LLLouise Lundby-Christensen

Louise Lundby-Christensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Louise Lundby-Christensen has a total of 139 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Educational outcomes and the role of comorbidity among adolescents with type 1‐diabetes in Denmark

    by Anne Bonde Thorsted, Lau Caspar Thygesen, Sofie Have Hoffmann, Siri Rosenkilde, Sara Fokdal Lehn, Louise Lundby‐Christensen, Trine Allerslev Horsbøl

    Aims: To examine educational outcomes among adolescents with type 1 diabetes and determine the role of comorbidity.Methods: We conducted a nationwide register‐based cohort study including 3370 individuals born between 1991 and 2003 and diagnosed with type 1 diabetes before the age of 16. They were all matched with up to four individuals without type 1 diabetes on age, gender, parents' educational level and immigration status. Information on comorbidity was based on hospital diagnoses. The individuals were followed in registers to determine whether they finished compulsory school (9th grade, usually at the age of 15–16 years), and were enrolled in secondary education by age 18 years.Results: Individuals with type 1 diabetes were more likely not to complete compulsory school (OR 1.44, 95% CI 1.26–1.64), and not being enrolled in an upper secondary education by age 18 (OR 1.50, 95% CI 1.31–1.73) compared to their peers. A total of 1869 (56%) individuals with type 1 diabetes were registered with at least one somatic (n = 1709) or psychiatric comorbidity (n = 389). Those with type 1 diabetes and psychiatric comorbidity were more likely not to complete compulsory school (OR 2.47, 95% CI 1.54–3.96), and not being enrolled in an upper secondary education by age 18 (OR 3.66, 95% CI 2.27–5.91) compared to those with type 1 diabetes only. Further, there was a tendency towards an association between having somatic comorbidity and adverse educational outcomes (OR 1.25, 95% CI 0.97–1.63; OR 1.26, 95% CI 0.95–1.66) among adolescents with type 1 diabetes. The associations differed markedly between diagnostic comorbidity groups.Conclusion: Type 1 diabetes affects educational attainment and participation among adolescents. Psychiatric comorbidity contributes to adverse educational outcomes in this group, and there is a tendency that somatic comorbidity also plays a role.

  • Open Access

    Development of video tutorials to help parents manage children with acute illnesses using a modified Delphi method

    by L. Borch‐Johnsen, L. Andrés‐Jensen, F. Folke, M. M. Espersen, S. L. Amstrup, M. S. Frederiksen, L. K. Gjærde, B. R. Hjelvang, M. J. Kristoffersen, L. Lundby‐Christensen, et al.

    Aim: Children often fall sick, which causes concern among parents. Online health information can be confusing and difficult to understand. We aimed to produce simple, informative video tutorials on the symptoms ill children present.Methods: We used a modified Delphi method to produce video tutorials on the symptoms of fever, vomiting and diarrhoea, abdominal pain, breathing difficulties, sore throat, red eyes, earache and rash. We identified the most common symptoms in acutely ill children. During the first consensus round, experts rated statements on out‐of‐hospital management from existing health information. Video tutorials were produced from statements rated to be included. The second consensus round involved video showings and editing. Two videos were evaluated in focus groups by parents.Results: During the first round, experts rated a median of 79 (40–154) statements for each symptom. Panels consisted of a median of seven (6–11) experts, primarily. Panels reached a consensus on inclusion, neutrality or exclusion in 83% of statements. The second round led to adjustments to the videos and final approval by experts. Most parents evaluated the videos as ‘informative, easy to understand and calming’.Conclusion: We produced video tutorials on the common symptoms ill children present using a modified Delphi method. Feedback from parents in focus groups was positive.


  • Open Access

    Effects of 18-months metformin versus placebo in combination with three insulin regimens on RNA and DNA oxidation in individuals with type 2 diabetes: A post-hoc analysis of a randomized clinical trial

    by Emil List Larsen, Laura K. Kjær, Louise Lundby-Christensen, Trine W. Boesgaard, Leif Breum, Christian Gluud, Christoffer Hedetoft, Thure Krarup, Søren S. Lund, Elisabeth R. Mathiesen, et al.


  • Prediction of carotid intima-media thickness and its relation to cardiovascular events in persons with type 2 diabetes

    by Karoline Winckler, Birger Thorsteinsson, Niels Wiinberg, Andreas Kryger Jensen, Louise Lundby-Christensen, Berit Lilienthal Heitmann, Søren S. Lund, Thure Krarup, Tonny Jensen, Henrik Vestergaard, et al.


  • Disruption, worries and autonomy in the everyday lives of adolescents with type 1 diabetes and their family members: A qualitative study of intrafamilial challenges

    by Mathilde Overgaard, Louise Lundby‐Christensen, Dan Grabowski

    Aim: To explore daily life with type 1 diabetes in families with an adolescent with type 1 diabetes.Background: Management of adolescent type 1 diabetes is carried out in the context of everyday life, thus involving and affecting the entire family. Type 1 diabetes causes disruption of family life, but the specific experiences and challenges of adolescents with type 1 diabetes, siblings and parents are not well‐explored. Specifically, research is lacking on the siblings’ experience of adolescents with type 1 diabetes.Design: A qualitative design using participatory workshops.Methods: A sample of 21 families comprising adolescents with type 1 diabetes (aged 8–18) (N = 20), their parents (N = 29) and siblings (N = 10) participated in four workshops exploring everyday life in families with adolescent diabetes from the perspective of all family members. Data were analysed using systematic text condensation. The COREQ checklist was used preparing the manuscript.Results: Family life with type 1 diabetes was characterised by three overarching themes: (a) the perpetual challenges and disruptive nature of life with diabetes, (b) different ways of worrying about diabetes and (c) diabetes autonomy and emancipation from parents. All family members’ lives were marked by these aspects, however in different ways and to varying degrees.Conclusions: Our findings emphasise that type 1 diabetes is indeed a family illness affecting all family members. The study provides insight into the unique experiences of adolescents with diabetes, their parents and siblings, all of whom encounter diabetes‐related challenges in their daily lives.Relevance to clinical practice: The findings call for the inclusion of all family members of adolescents with type 1 diabetes in both research and healthcare practice. Family‐oriented approaches targeting adolescents with diabetes as well as their parents and siblings will enable provision of nursing care that can meet the needs of the entire family.


  • Progression in risk factors during 36 years of follow-up and prediction of carotid intima-media thickness in a large cohort of adults with and without diabetes

    by Karoline Winckler, Niels Wiinberg, Andreas Kryger Jensen, Birger Thorsteinsson, Louise Lundby-Christensen, Berit Lilienthal Heitmann, Gorm Boje Jensen, Lise Tarnow

    Carotid intima-media thickness (IMT) can assess the cumulative effect of atherosclerotic risk factors and provides an independent predictor of future cardiovascular (CV) risk. The aim of this study was to investigate the progression of conventional risk factors in 933 long-term survivors from a Danish cohort with and without diabetes mellitus (DM) as predictors for attained carotid IMT during 35.6 (0.7) years of follow-up. Persons who participated in the first, the last and one of the intermediate rounds of the Copenhagen City Heart Study, and who had had an ultrasound-derived measure of the carotid IMT performed at the last examination were included in the analyses. The risk factors varied between persons with and without DM during the 36 years, but the difference in blood pressure disappeared in the fifth examination, where, in addition, total cholesterol was found to be lower in persons with DM. In this cohort there were no difference in attained carotid IMT between persons with and without DM at the last examination. The following risk factors were found to best predict carotid IMT: age, maximum systolic BP, average systolic BP, average BMI, minimum BMI, sex and years of smoking. The prediction of carotid IMT was clinically poor with a root mean-squared error of prediction (RMSEP) of 0.134 mm and a 95% prediction error probability interval of (−0.22; 0.30). Furthermore, the distribution of prediction errors was skewed to the right indicating that the prediction errors were larger among persons with high carotid IMT.


  • Effect of Metformin vs. Placebo in Combination with Insulin Analogues on Bone Markers P1NP and CTX in Patients with Type 2 Diabetes Mellitus

    by Azra Karahasanovic Nordklint, Thomas Peter Almdal, Peter Vestergaard, Louise Lundby-Christensen, Niklas Rye Jørgensen, Trine W. Boesgaard, Leif Breum, Birthe Gade-Rasmussen, Simone B. Sneppen, Christian Gluud, et al.

    Preclinical studies have shown a potential osteoanabolic effect of metformin but human studies of how metformin affects bone turnover are few. A post hoc sub-study analysis of an 18-month multicenter, placebo-controlled, double-blinded trial in type 2 diabetes mellitus (T2DM), randomizing participants to metformin versus placebo both in combination with different insulin analogue regimens (Metformin + Insulin vs. Placebo + Insulin). Patients were not treatment naive at baseline, 83% had received metformin, 69% had received insulin, 57.5% had received the combination of metformin and insulin before entering the study. Bone formation and resorption were assessed by measuring, N-terminal propeptide of type I procollagen (P1NP) and C-terminal telopeptide of type I collagen (CTX) at baseline and end of study. The influence of gender, age, smoking, body mass index (BMI), T2DM duration, glycosylated hemoglobin A1c (HbA1c), c-reactive protein (CRP) and insulin dosage was also included in the analyses. The levels of bone formation marker P1NP and bone resorption marker CTX increased significantly in both groups during the trial. P1NP increased less in the Metformin + Insulin compared to the placebo + insulin group (p = 0.001) (between group difference change), while the increases in CTX levels (p = 0.11) were not different. CRP was inversely associated (p = 0.012) and insulin dosage (p = 0.011) was positively related with change in P1NP levels. BMI (p = 0.002) and HbA1C (p = 0.037) were inversely associated with change in CTX levels. During 18 months of treatment with metformin or placebo, both in combination with insulin, bone turnover increased in both groups. But the pattern was different as the bone formation marker (P1NP) increased less during Metformin + Insulin treatment, while change in bone resorption (CTX) was not significantly different between the two groups.


  • Carotid intima media thickness and ankle brachial index are inversely associated in subjects with and without diabetes

    by Karoline Winckler, Niels Wiinberg, Andreas Kryger Jensen, Birger Thorsteinsson, Louise Lundby-Christensen, Berit Lilienthal Heitmann, Gorm Boje Jensen, Lise Tarnow

    Carotid intima-media thickness (IMT) and ankle brachial index (ABI) are non-invasive indicators of generalised atherosclerosis. The aim was to determine the association between carotid IMT and ABI in subjects with and without diabetes mellitus (DM), and to analyse specific age change-points. We included 2744 subjects from the Copenhagen City Heart Study (mean age (SD) 56.6 (17.2) years, 56.8% women and body mass index (BMI) 25.4 (4.1) kg/m2). Carotid IMT and ABI measurements were performed during the fifth examination. Of the 2744 subjects, 125 subjects (4.6%) had DM. Average carotid IMT was 0.667 (0.145) mm and ABI was 1.06 (0.14). Subjects with DM were older, had higher BMI and systolic blood pressure (SBP) (all p < .001). Carotid IMT was higher in subjects with DM (0.754 (0.150) mm) compared to subjects without DM (0.662 (0.144) mm) (p < .001), whereas there was no difference in ABI between the two groups. ABI was inversely associated with carotid IMT (slope = −0.17 [−0.207; −0.137] (p < .001). The association remained significant after adjustment for risk factors both in subjects with DM (slope = −0.168 [−0.328; −0.007], p = .040), and in subjects without DM (slope = −0.100 [−0.148; −0.052], p < .001), with a stronger effect of carotid IMT on ABI among subjects with DM. Carotid IMT and ABI were inversely associated in subjects with DM and without DM, but with a stronger effect in subjects with DM. Age and ABI revealed a change-point with a stronger inverse association among subjects aged >60 years.


  • The effect of metformin versus placebo in combination with insulin analogues on bone mineral density and trabecular bone score in patients with type 2 diabetes mellitus: a randomized placebo-controlled trial

    by A. K. Nordklint, T. P. Almdal, P. Vestergaard, L. Lundby-Christensen, T. W. Boesgaard, L. Breum, B. Gade-Rasmussen, S. B. Sneppen, C. Gluud, B. Hemmingsen, et al.

    Some antihyperglycemic medications have been found to affect bone metabolism. We assessed the long-term effects of metformin compared with placebo on bone mineral density (BMD) and trabecular bone score (TBS) in patients with type 2 diabetes. Metformin had no significant effect on BMD in the spine and hip or TBS compared with a placebo.


  • Open Access

    Prediction of excessive weight gain in insulin treated patients with type 2 diabetes

    by Simon Lebech Cichosz, Louise Lundby‐Christensen, Mette D. Johansen, Lise Tarnow, Thomas Peter Almdal, Ole K. Hejlesen, The C.I.M.T. Trial Group

    Background: Weight gain is an ongoing challenge when initiating insulin therapy in patients with type 2 diabetes mellitus (T2DM). However, if prediction of insulin‐associated weight gain was possible on an individual level, targeted initiatives could be implemented to reduce weight gain. The aim of the present study was to identify predictors of weight gain in insulin‐treated patients with T2DM.Methods: In all, 412 individuals with T2DM were, in addition to metformin or placebo, randomized into 18‐month treatment groups with three different insulin analog treatment regimens (biphasic, aspart, detemir). Participants with excessive weight gain were defined as the group with weight gain in the 4th quartile (>6.2 kg).We developed a pattern classification method to predict individuals prone to excessive weight gain.Results: Over the 18‐month treatment period, median weight gain among all 412 patients was 2.4 kg (95% prediction interval [PI] –5.6, 12.4 kg), whereas median weight gain for those in the upper 4th quartile (n = 103) was 8.9 kg (95% PI 6.3, 15.2 kg). No clinical baseline data were strong predictors of excessive weight gain. However, the weight gain during the first 3 months of the trial and the subsequent dose of insulin yielded a useful predictor for weight gain at the 18‐month follow‐up. Combining these two predictors into a prediction model with other clinical available information produced a receiver operating characteristic area under the curve of 0.80.Conclusions: We have developed a prediction model that could help identify a substantial proportion of individuals with T2DM prone to large weight gain during insulin therapy.